Alnylam Pharmace. buy Stifel Nicolaus
Start price
06.10.25
/
50%
€387.60
Target price
06.10.26
€422.24
Performance (%)
-9.62%
Price
16:00
€350.30
Summary
This prediction is currently active. With a performance of -9.62%, the BUY prediction for Alnylam Pharmace. by Stifel_Nicolaus is down slightly. This prediction currently runs until 06.10.26. The prediction end date can be changed by Stifel_Nicolaus at any time. Stifel_Nicolaus has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | 1.240% | 1.240% |
| iShares Core DAX® | 2.659% | 4.844% |
| iShares Nasdaq 100 | 0.916% | -0.554% |
| iShares Nikkei 225® | 2.426% | 1.598% |
| iShares S&P 500 | 1.230% | 1.039% |
Comments by Stifel_Nicolaus for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Stifel Nicolaus from $441.00 to $495.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Stifel_Nicolaus for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€228.70
27.06.24
27.06.24
€275.15
27.06.25
27.06.25
20.16%
28.06.25
28.06.25
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€181.40
14.09.23
14.09.23
€225.00
14.09.24
14.09.24
32.41%
15.09.24
15.09.24